|
Baseline characteristics of patients with mild-moderate Alzheimer's disease who were treated with donepezil for 6 months, by ADAS-Cog response group |
||||
| All patients |
ADAS-Cog |
ADAS-Cog |
ADAS-Cog |
|
| (n = 95) |
improved |
no change |
worsened |
|
| (n = 19) |
(n = 53) |
(n = 23) |
||
|
|
||||
| Baseline characteristics |
||||
| Females, n (%) |
68 (72) |
15 (79) |
36 (68) |
17 (74) |
| Age, mean years (sd) |
75.8 (7.7) |
79.8 (8.2) |
75.5 (6.3) |
73.3 (8.9) |
| Education, mean years (sd) |
11.1 (3.2) |
10.5 (3.2) |
11.0 (3.2) |
11.6 (3.2) |
| Duration of illness, mean years (sd) |
1.3 (1.5) |
1.0 (1.0) |
1.3 (1.7) |
1.5 (1.6) |
| CDR = mild, n (%) |
73 (77) |
14 (74) |
44 (83) |
15 (65) |
| Baseline outcomes |
||||
| CIBIS+, mean (sd) |
3.7 (0.8) |
3.7 (0.8) |
3.6 (0.7) |
3.9 (0.7) |
| MMSE, mean (sd) |
19.9 (5.3) |
20.0 (4.7) |
20.6 (5.3) |
18.3 (5.4) |
| ADAS-Cog, mean (sd) |
24.6 (9.9) |
26.4 (10.6) |
23.2 (9.3) |
26.3 (10.4) |
| PSMS, mean (sd) |
8.8 (2.5) |
9.3 (2.1) |
8.8 (2.7) |
8.3 (2.2) |
| IADL, mean (sd) |
19.9 (5.4) |
20.5 (4.6) |
20.1 (5.4) |
18.9 (6.1) |
| CSD, mean (sd) |
5.7 (5.4) |
6.4 (5.5) |
5.5 (5.1) |
5.9 (6.2) |
| Treatment goals set at baseline |
||||
| PGAS-total, mean (sd) |
8.6 (3.3) |
8.2 (2.7) |
8.7 (3.3) |
8.6 (3.8) |
| PGAS-cognition, mean (sd)1 |
1.2 (0.8) |
1.1 (0.7) |
1.2 (0.8) |
1.2 (0.7) |
| CGAS-total, mean (sd) |
3.4 (1.3) |
3.1 (0.8) |
3.5 (1.4) |
3.3 (1.2) |
| CGAS-cognition, mean (sd)2 |
2.1 (1.8) |
2.5 (2.3) |
2.2 (1.7) |
1.8 (1.4) |
|
1 81/95 patients/caregivers set cognition goals: respectively 16/19, 45/53 and, 20/23 2 81/95 clinicians set cognition goals, respectively 17/19, 45/53 and 19/23 | ||||
Rockwood et al. BMC Neurology 2007 7:26 doi:10.1186/1471-2377-7-26 |
||||